Correcting Disinformation About Menthol Cigarettes and Flavored Cigars
The Unvarnished Truth: Pursuing Health Equity by Correcting Disinformation Targeting African Americans About the FDA's Proposed Ban on Menthol Cigarettes and Flavored Cigars
2 other identifiers
interventional
1,000
1 country
1
Brief Summary
Our study tests a multi-level anti- disinformation message (ADM) campaign on menthol cigarette and flavored cigar policies in Black adults.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for not_applicable
Started Sep 2026
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
April 15, 2026
CompletedFirst Posted
Study publicly available on registry
April 21, 2026
CompletedStudy Start
First participant enrolled
September 1, 2026
ExpectedPrimary Completion
Last participant's last visit for primary outcome
January 31, 2028
Study Completion
Last participant's last visit for all outcomes
January 31, 2028
May 5, 2026
April 1, 2026
1.4 years
April 15, 2026
April 29, 2026
Conditions
Outcome Measures
Primary Outcomes (3)
Proportion of participants with specific tobacco industry beliefs
Beliefs items address tobacco industry behaviors, including funding Black community organizations, paying Black lobbyists to oppose public health policies, and targeting Black and African American communities with menthol cigarette and flavored cigar marketing.
3, 6, 9, 12 months
Knowledge about menthol cigarettes and flavored cigars
Items address prevalence of menthol cigarette and flavored cigar use in Black and African Americans and role of menthol/flavors in tobacco initiation, progression, and cessation.
3, 6, 9, 12 months
Knowledge of flavored tobacco policies
Items address the public health purpose and limits of flavored tobacco policies.
3, 6, 9, 12 months
Secondary Outcomes (1)
Intention to support flavored tobacco policies
3, 6, 9, 12 months
Study Arms (4)
Individual-level intervention + Community-level intervention
EXPERIMENTALIndividual-level control + Community-level intervention
EXPERIMENTALIndividual-level intervention + Community-level control
EXPERIMENTALIndividual-level control + Community-level control
NO INTERVENTIONInterventions
Participants in this condition will be exposed to anti-disinformation messages (ADM) designed to increase correct beliefs about menthol cigarettes, flavored cigars, the purpose, and limits of flavored tobacco policies. The delayed intervention control condition in this study will receive the ADM intervention after outcome measures are collected at the last assessment.
Our community-level campaign will distribute our ADM messages to our Intervention Community via social media, print ads and posters, radio ads, and community events. These messages will be delivered over 1 year, with monthly delivery activities led by EAB members in the Intervention Community.
Eligibility Criteria
You may qualify if:
- African American or Black adults
- Aged 18+
- Reside in Atlanta, GA or Birmingham, AL
- Able to read and speak English
- Willing to engage in all online study activities including online quarterly surveys over a 12-month period.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Rutgers University
New Brunswick, New Jersey, 08901, United States
Related Publications (4)
Ganz O, Villanti AC, Altunbilek A, Johnson A, Garmon J, Wackowski OA, Sterling KL. Tobacco Company Efforts to Persuade Consumers to Fight the Proposed Federal Menthol Cigarette and Flavored Cigar Bans in the United States. Am J Public Health. 2025 Aug;115(8):1206-1210. doi: 10.2105/AJPH.2025.308116. No abstract available.
PMID: 40633013BACKGROUNDWackowski OA, Garmon J, Altunbilek A, Johnson A, Ganz O, Ntansah CA, Fryer CS, Villanti AC, Sterling KL. News Coverage of the Proposed Menthol Cigarette Ban in the United States (2022-2024) - a Content Analysis. Nicotine Tob Res. 2026 Feb 18:ntag036. doi: 10.1093/ntr/ntag036. Online ahead of print.
PMID: 41705314BACKGROUNDGarmon J, Sterling K, Wackowski OA, Ganz O, Allem JP, Villanti AC. Funding without transparency? Tobacco company support of Black-owned businesses in the USA. Tob Control. 2024 Nov 19:tc-2024-058721. doi: 10.1136/tc-2024-058721. Online ahead of print. No abstract available.
PMID: 39561998BACKGROUNDSterling KL, Ganz O, Wackowski OA, Glasser AM, Villanti AC. Widespread Misperceptions Among U.S. Adults About Tobacco Company Engagement in Black and African American Communities. Nicotine Tob Res. 2025 Mar 24;27(4):741-747. doi: 10.1093/ntr/ntae066.
PMID: 38692654BACKGROUND
Related Links
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Andrea C Villanti, PhD, MPH
Rutgers University
- PRINCIPAL INVESTIGATOR
Kymberle L Sterling, DrPH
Rutgers University
Central Study Contacts
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- NONE
- Purpose
- BASIC SCIENCE
- Intervention Model
- FACTORIAL
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Professor
Study Record Dates
First Submitted
April 15, 2026
First Posted
April 21, 2026
Study Start (Estimated)
September 1, 2026
Primary Completion (Estimated)
January 31, 2028
Study Completion (Estimated)
January 31, 2028
Last Updated
May 5, 2026
Record last verified: 2026-04
Data Sharing
- IPD Sharing
- Will share
- Shared Documents
- STUDY PROTOCOL
- Time Frame
- IPD and supporting information will be available approximately 12 months following the end of data collection or publication of the main study outcomes.
- Access Criteria
- Study data will be deposited in the NAHDAP data repository hosted at the ICPSR and will be available to the research community in perpetuity. Datasets underlying methodological publications will be shared at or prior to initial publication date.
Deidentified survey responses from participants enrolled in the clinical trial.